Yartsev Vasily D, Solodkiy Vladimir A, Fomin Dmitriy K, Borisenko Tatiana E, Atkova Eugenia L
Lacrimal Pathology Department, Federal State Budgetary Research Institution "Research Institute of Eye Diseases", Moscow, Russia.
Head Office, Federal State Budgetary Institution "Russian Scientific Center of Roentgenology and Radiology" of the Ministry of Health of Russia, Moscow, Russia.
Curr Eye Res. 2021 Sep;46(9):1320-1324. doi: 10.1080/02713683.2021.1878229. Epub 2021 Jan 25.
: Radioiodine ablation is a frequent procedure for the management of thyroid cancer. In several cases, this treatment is followed by secondary acquired nasolacrimal duct obstruction (SALDO). Risk factors for the development of SALDO are not defined yet.Aim - to provide clinical and demographic characteristics of tearing in patients after radioiodine treatment.: Material was obtained by a phone survey of 588 patients who underwent radioiodine treatment. Age and gender of the respondent, strength of administered medication, and time since the end of treatment were taken into account. Patients were asked if they had dry mouth and/or tearing at the time of the survey. Differences in values were found using parametric and nonparametric criteria, Pearson's χ test. Differences were considered statistically significant at p ≤ 0.05.: Severe tearing was reported by 8.8% of patients after single-dose radioiodine treatment and 23.9% of patients after repeated one. The age of patients with severe tearing and without it showed statistically significant difference in patients after single-dose radioiodine treatment and no statistically significant difference in patients after repeated radioiodine treatment. Administration of 4 GBq or more in patients aged 61-71 years results in 4-fold increase of the risk of severe tearing. Dry mouth causes 3.6-fold increase of the risk of developing severe tearing.: Finding risk factors for SALDO development after radioiodine therapy in the future will contribute to an individualized approach to the prevention of this complication. Development of preventive measures is one of the tasks facing researchers.
放射性碘消融是甲状腺癌治疗中常用的方法。在一些病例中,这种治疗后会继发获得性鼻泪管阻塞(SALDO)。SALDO发生的危险因素尚未明确。目的——提供放射性碘治疗后患者流泪的临床和人口统计学特征。材料通过对588例接受放射性碘治疗的患者进行电话调查获得。考虑了受访者的年龄和性别、所用药物的剂量以及治疗结束后的时间。询问患者在调查时是否有口干和/或流泪。使用参数和非参数标准、Pearson卡方检验来发现数值差异。当p≤0.05时,差异被认为具有统计学意义。单剂量放射性碘治疗后8.8%的患者报告有严重流泪,重复治疗后这一比例为23.9%。单剂量放射性碘治疗后,有严重流泪和无严重流泪患者的年龄存在统计学显著差异,而重复放射性碘治疗后的患者则无统计学显著差异。61 - 71岁患者给予4GBq或更高剂量会使严重流泪风险增加4倍。口干会使发生严重流泪的风险增加3.6倍。未来找到放射性碘治疗后SALDO发生的危险因素将有助于采取个体化方法预防这种并发症。制定预防措施是研究人员面临的任务之一。